Intranasal Midazolam Dosing for Pediatric Sedation

Comparative Efficacy Evidence

Intranasal midazolam at 0.5 mg/kg was inferior to IV ketamine/midazolam combination for laceration repair, with only 54% physician satisfaction versus 88% with IV ketamine/midazolam, suggesting that while 0.2-0.3 mg/kg intranasal midazolam is appropriate for anxiolysis and mild sedation, more painful procedures may require alternative agents or routes 1, 2

The American Academy of Pediatrics warns of significantly increased apnea risk when midazolam is combined with opioids, requiring particular vigilance and readiness to provide respiratory support 3

Flumazenil must be readily available to reverse life-threatening respiratory depression at a dose of 0.01 mg/kg, with the caveat that it will reverse anticonvulsant effects and may precipitate seizures if midazolam was used for seizure control 4

Do not use intranasal midazolam as sole agent for painful procedures requiring deep sedation—consider ketamine or other alternatives, as evidenced by studies comparing intranasal midazolam to IV ketamine/midazolam combination 1, 2
Avoid combining midazolam with other sedatives, particularly opioids, without appropriate monitoring and airway management capabilities, as warned by the American Academy of Pediatrics 3
Ensure qualified personnel trained in pediatric airway management are present throughout the sedation period when administering midazolam 4

The American Academy of Pediatrics recommends a midazolam dose of 0.05-0.10 mg/kg intravenously given over 2-3 minutes for sedation/anxiolysis in pediatric patients, with a maximum single dose of 5 mg 5, 6, 7

For intravenous sedation/anxiolysis in pediatric patients, a dose of 0.05-0.10 mg/kg given over 2-3 minutes is recommended, with peak effect occurring at 3-5 minutes after administration 5
The dose for adjunct to endotracheal intubation is 0.2 mg/kg, allowing 2-3 minutes for effect before administering muscle relaxant 5
For oral administration, a dose of 0.25-0.50 mg/kg, with a maximum of 20 mg, is recommended, while children under 6 years old may require up to 1 mg/kg 5

There is an increased risk of apnea when midazolam is combined with other sedative agents, particularly opioids, and respiratory support should always be available 5, 8
Continuous monitoring of oxygen saturation is essential when administering midazolam 8
Paradoxical agitation may occur, especially in younger pediatric patients, and should be carefully monitored 5

Flumazenil may be administered to reverse life-threatening respiratory depression caused by midazolam, but it will also reverse the anticonvulsant effects and may precipitate seizures if midazolam was used for seizure control 5, 8

The combination of fentanyl and midazolam is effective for procedural sedation but requires extreme caution, as recommended by the American College of Emergency Physicians 9
Continuous oxygen saturation monitoring is mandatory, as respiratory depression is the most serious adverse event, with oxygen desaturation occurring in 11.6% of patients receiving midazolam for procedural sedation, according to the American Academy of Pediatrics 10
Midazolam alone was significantly less effective than pentobarbital for CT sedation in one Class II randomized trial, with only 19% successful scans with midazolam versus 97% with pentobarbital, as reported by the American College of Radiology 11